Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
作者信息
Ray-Coquard Isabelle, Vanacker Hélène, Le Saux Olivia, Tredan Olivier
机构信息
Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon 69008, France; University Claude Bernard Lyon 1, Lyon, France.
Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon 69008, France; University Claude Bernard Lyon 1, Lyon, France.
出版信息
EBioMedicine. 2020 Nov;61:103046. doi: 10.1016/j.ebiom.2020.103046. Epub 2020 Oct 7.
Abstract
摘要
相似文献
1
Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
EBioMedicine. 2020 Nov;61:103046. doi: 10.1016/j.ebiom.2020.103046. Epub 2020 Oct 7.
2
PARP inhibitors in ovarian and other cancers.
Clin Adv Hematol Oncol. 2015 May;13(5):285-7.
3
When in the treatment continuum to use PARP inhibition in ovarian cancer.
Clin Adv Hematol Oncol. 2021 Feb;19(2):84-86.
4
The current status of PARP inhibitors in ovarian cancer.
Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
5
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Ovarian Cancer Cells.
Mol Cancer Ther. 2020 Jan;19(1):199-210. doi: 10.1158/1535-7163.MCT-19-0242. Epub 2019 Sep 18.
6
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Arch Gynecol Obstet. 2020 Nov;302(5):1087-1102. doi: 10.1007/s00404-020-05677-1. Epub 2020 Aug 24.
7
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Curr Drug Targets. 2020;21(2):167-178. doi: 10.2174/1389450120666190925123507.
8
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations.
Cancer Treat Rev. 2021 Sep;99:102255. doi: 10.1016/j.ctrv.2021.102255. Epub 2021 Jul 15.
9
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
Curr Opin Obstet Gynecol. 2019 Feb;31(1):4-11. doi: 10.1097/GCO.0000000000000507.
10
PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.
Oncol Res Treat. 2018;41(4):226-235. doi: 10.1159/000486418. Epub 2018 Mar 23.
引用本文的文献
1
Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade.
Int J Mol Sci. 2023 Jun 30;24(13):10966. doi: 10.3390/ijms241310966.
2
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
Sci Rep. 2023 Feb 27;13(1):3334. doi: 10.1038/s41598-023-30081-5.
3
Study of Ferroptosis Transmission by Small Extracellular Vesicles in Epithelial Ovarian Cancer Cells.
Antioxidants (Basel). 2023 Jan 12;12(1):183. doi: 10.3390/antiox12010183.
4
AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization.
Cancers (Basel). 2022 Jan 8;14(2):304. doi: 10.3390/cancers14020304.
5
Downregulation of the Coiled-Coil Domain Containing 80 and Its Perspective Mechanisms in Ovarian Carcinoma: A Comprehensive Study.
Int J Genomics. 2021 Nov 15;2021:3752871. doi: 10.1155/2021/3752871. eCollection 2021.
本文引用的文献
1
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
EBioMedicine. 2020 Oct;60:102988. doi: 10.1016/j.ebiom.2020.102988. Epub 2020 Sep 11.
2
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
3
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.
4
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
5
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
J Clin Oncol. 2019 Nov 10;37(32):2968-2973. doi: 10.1200/JCO.18.02238. Epub 2019 Jun 7.
6
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
7
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
PLoS One. 2018 Jul 23;13(7):e0200826. doi: 10.1371/journal.pone.0200826. eCollection 2018.
8
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.
9
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.
10
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.
Zotero 插件